On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.
The Consolidated Appropriations Act of 2026 features new language that could change the way that pharmacy benefit managers (PBMs) operate in the US.
Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales ...
Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong demand for newer immunology drugs Skyrizi and ...
Zacks.com on MSN
GSK (GSK) Surpasses Q4 Earnings and Revenue Estimates
GSK (GSK) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.59 per share a year ago. These figures are ...
Zacks Investment Research on MSN
AbbVie (ABBV) Q4 earnings: Taking a look at key metrics versus estimates
For the quarter ended December 2025, AbbVie (ABBV) reported revenue of $16.62 billion, up 10% over the same period last year. EPS came in at $2.71, compared to $2.16 in the year-ago quarter. The ...
Dublin Airport recorded a 14 per cent jump in the number of passengers travelling... US airlines have upped the ante in the long-running dispute over the Dublin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results